Pharsight

Tafinlar patents expiration

TAFINLAR's oppositions filed in EPO
Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8415345 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(5 years from now)

US7994185 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jan, 2030

(5 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(1 year, 3 months from now)

US8835443

(Pediatric)

NOVARTIS Pyrimidine compound and medical use thereof
Dec, 2025

(1 year, 9 months from now)

US9233956 NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
May, 2029

(5 years from now)

US9233956

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Nov, 2029

(5 years from now)

US8415345

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jul, 2030

(6 years from now)

US7994185

(Pediatric)

NOVARTIS Benzene sulfonamide thiazole and oxazole compounds
Jul, 2030

(6 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Oct, 2030

(6 years from now)

US8703781

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Apr, 2031

(7 years from now)

US8952018

(Pediatric)

NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Apr, 2031

(7 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment
Aug, 2033

(9 years from now)

US10869869

(Pediatric)

NOVARTIS Method of adjuvant cancer treatment
Mar, 2034

(10 years from now)

US11504333 NOVARTIS Pharmaceutical composition
Jun, 2038

(14 years from now)

Tafinlar is owned by Novartis.

Tafinlar contains Dabrafenib Mesylate.

Tafinlar has a total of 15 drug patents out of which 0 drug patents have expired.

Tafinlar was authorised for market use on 29 May, 2013.

Tafinlar is available in capsule;oral dosage forms.

Tafinlar can be used as tafinlar is indicated, in combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy, tafinlar(r) is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection, tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.; treatment of melanoma; tafinlar is indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test, tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test.; tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; treatment of patients with unresectable or metastatic melanoma with braf v600e mutations after confirming the presence of braf v600e mutation; tafinlar is indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with braf v600e mutation as detected by an fda-approved test, tafinlar(r) is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test., tafinlar is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; tafinlar in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma; tafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test..

The generics of Tafinlar are possible to be released after 29 June, 2038.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 16, 2030
New Indication (I) Jun 22, 2025
Pediatric Exclusivity (PED) Dec 22, 2025

Drugs and Companies using DABRAFENIB MESYLATE ingredient

Market Authorisation Date: 29 May, 2013

Treatment: Tafinlar is indicated, in combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic thera...

Dosage: CAPSULE;ORAL

More Information on Dosage

TAFINLAR family patents

Family Patents